SCOPE Summit 2026 in Orlando, Florida, welcomed more than 4,500 clinical research professionals for a week dedicated to insights, innovation, and meaningful connection. With dozens of focused sessions and hundreds of expert speakers, the event brought together sponsors, CROs, tech innovators, and patient recruitment specialists to share perspectives, spark new collaborations, and help shape the next chapter of clinical trials.
For Clariness, it was more than just another conference, it was a milestone week.
Key highlights from SCOPE 2026:
- A full-house session debunking industry myths with expert guest speakers from Amgen, Bristol Myers Squibb & Takeda
- Our very first public appearance with SubjectWell, as one unified team
- Record-breaking client meetings, and raised the bar higher than ever
Taking myths to the stage: The patient recruitment reality check
One of the highlights of the week was our live panel session, “The Patient Recruitment Reality Check” hosted by George Dorsett, featuring:
- Alex Weir, Sr. Director & Head of Operational Design, Clinical Program Operations, Amgen
- Michele Falk, Associate Director, R&DD Global Patient Outreach Recruitment Lead, Bristol Myers Squibb
- Amanda Decoker, Sr. Director, Head of Patient Engagement, Experience and Recruitment, Takeda
Together we debated three of the biggest myths shaping our industry and challenged long-standing assumptions around (digital) patient recruitment.
Watch our full SCOPE Presentation below:
The appetite for realism stood out the most, reinforcing something we hear again and again: patient recruitment success rarely comes down to one lever. It is about strategy, structure, execution, and timing.
Clariness & SubjectWell
SCOPE 2026 marked the launch of the new Clariness, marking our first public appearance with SubjectWell. Being present together at one of the industry’s most influential events represented an exciting step forward and demonstrated the strength of our aligned expertise.
Earlier this week, Clariness and SubjectWell officially joined forces, not simply to grow, but to reshape how patient enrollment works across the life sciences ecosystem.
By combining global infrastructure, technology, and human expertise, we are building something stronger, more connected, and more reliable for sponsors, CROs, and patients alike.
Read how this merger matters for sponsors, CROs, and patients here: Clariness + SubjectWell: Why this merger matters – Clariness
Beyond the stage: conversations that matter
The week was filled with engaging exchanges and meaningful connections with industry experts.
Throughout SCOPE, the new Clariness team engaged in impactful conversations with sponsors, CROs, and industry experts. The enthusiasm and interest around our brand and global expertise underscored the increasing demand for scalable, performance-driven clinical trial partnerships.
The momentum translated into a record number of client meetings, raising the bar higher than ever, and setting a new benchmark for our presence at SCOPE – which is why we’ve already booked a bigger space for next year, and more speaking slots with customers.
Here’s what our team at SCOPE 2026 said:
Looking Ahead
SCOPE 2026 was not just a successful event, it was a reminder that progress in clinical trials requires transparency, collaboration, and the courage to challenge assumptions.
We are grateful to everyone who joined our session, visited our booth, and contributed to meaningful conversations throughout the week.
The dialogue doesn’t have to end here.
If you would like to continue the conversation about how Clariness supports clinical trials globally, we would love to connect.